What's Going On With Autonomix Medical Stock Monday?

Zinger Key Points
  • The United States Patent and Trademark Office granted Autonomix patent 12,064,256.
  • The patent is titled Systems and Methods for Treating Cancer and/or Augmenting Organ Function.

Autonomix Medical, Inc. AMIX shares are moving higher on Monday after the company announced it was granted a U.S. patent titled Systems and Methods for Treating Cancer and/or Augmenting Organ Function.

What To Know: The patent encompasses technology for systems, methods and devices designed to treat cancerous tumors and manage cancer-related pain through interventional techniques. The company is first focusing on developing its technology to treat pain associated with pancreatic cancer.

In a previously conducted preclinical mouse study, the company demonstrated that targeted nerve ablation resulted in a statistically significant reduction of metastases and tumor mass. While Autonomix is currently conducting a human clinical trial focused on pain reduction using this technology, it plans to explore in future studies whether this ablation technology can also slow pancreatic cancer growth and metastasis.

Related Link: Why Is White Label Technology Company SMX Stock Surging On Monday?

AMIX Price Action: At the time of publication, Autonomix stock is trading 18.8% higher at $3.92, according to data from Benzinga Pro.

Image: Image: Akava Photo from Pixabay

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!